Kenvue Inc.

Kenvue Inc. is the world's largest pure-play consumer health company by revenue, with $15.1 billion in net sales in fiscal 2025 and a portfolio of iconic brands including Tylenol, Listerine, Neutrogena, BAND-AID, and Zyrtec sold across more than 165 countries. Spun off from Johnson & Johnson in 2023 and now the subject of an agreed merger with Kimberly-Clark, Kenvue is simultaneously a three-year-old standalone entity still disentangling from its former parent and a century-old collection of category-leading brands whose consumer franchises are the point of the enterprise.

The investment file turns on a single question: whether Kenvue's brand portfolio can generate reliable, compounding earnings growth as a standalone business, or whether its value is best realized inside a larger combination that can strip out the self-inflicted complexity the company's own management has acknowledged. The K-C merger, announced in November 2025 and approved by shareholders in January 2026, renders this a live question — but not an abstract one. If the deal closes, Kenvue shareholders will own roughly 46% of the combined company and the standalone thesis becomes moot; if it fails, they are left with a business that posted declining organic sales in 2025, guided for further declines, and was in the middle of a strategic review whose conclusions were never disclosed because the merger intervened.

This is a story about brand equity that has outlived its operating model. The products are trusted, the categories are stable, the margins are healthy — and yet the company has not translated any of that into consistent growth since the separation. The merger may resolve the question; if it doesn't, the answer will have to come from inside.